TPG to sell Par Pharma to Endo in $8.05 bln deal

By Luisa Beltran — 9 months ago

Endo International said Monday it has agreed to buy Par Pharmaceutical Holdings Inc. from TPG Capital in a deal valued at $8.05 billion, including debt. The boards of Endo and Par have both approved the deal. The purchase includes about 18 million Endo shares and $6.5 billion cash to Par shareholders. Deutsche Bank and Barclays are providing financing. TPG acquired Par, a generic drug maker, in 2012 in a $1.9 billion deal. Barclays, Deutsche Bank, and Houlihan Lokey acted as financial advisors to Endo. JP Morgan acted as financial advisor to Par.


TPG adds new media relations executives-Reuters

By Reuters News — 9 months ago

TPG Capital LP, the U.S. private equity firm that fired its spokesman and is suing him for allegedly leaking confidential documents to the media, has hired Luke Barrett as Director of External Affairs based in New York, the company said Monday.